Department of Surgery, Tokai University School of Medicine, 143 Shimokasuya Isehara, Kanagawa, 259-1193, Japan.
Anticancer Res. 2013 Aug;33(8):3431-8.
To identify the genes and clinical parameters associated with efficacy of uracil and tegafur/leucovorin (UFT/LV) chemotherapy in colorectal cancer (CRC), we compared the levels of reduced folate in tumors between patients receiving LV and those not receiving LV (study I), and explored the changes in the expression levels of 14 genes after two weeks of UFT/LV chemotherapy in 73 patients with CRC (study II). In study I, the reduced folate levels after LV administration were approximately 3-fold higher than those without LV administration in patients with right-sided tumors or aged >75 years old (p=0.019). In study II, the reduction in γ-glutamyl hydrolase (GGH) expression in responders and in patients with right-sided tumors or aged >75 years old was significantly greater than that in non-responders (p<0.001) and in other patients, respectively (p=0.003). Increase of reduced folate and reduction in GGH expression were associated with response to UFT/LV chemotherapy in patients with right-sided tumors or aged >75 years old.
为了鉴定与结直肠癌（CRC）中尿嘧啶和替加氟/亚叶酸（UFT/LV）化疗疗效相关的基因和临床参数，我们比较了接受 LV 治疗和未接受 LV 治疗的患者（研究 I）肿瘤中还原叶酸的水平，还研究了 73 例 CRC 患者接受 UFT/LV 化疗 2 周后 14 个基因表达水平的变化（研究 II）。在研究 I 中，右半结肠癌或年龄>75 岁的患者接受 LV 治疗后，还原叶酸水平大约是未接受 LV 治疗患者的 3 倍（p=0.019）。在研究 II 中，与非应答者相比（p<0.001），应答者和右半结肠癌或年龄>75 岁的患者的 γ-谷氨酰水解酶（GGH）表达降低更为显著（p=0.003）。右半结肠癌或年龄>75 岁的患者 UFT/LV 化疗的反应与还原叶酸的增加和 GGH 表达的降低相关。
